查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1552896

细胞化验分析市场规模、份额和趋势分析报告：按产品/服务、应用、最终用途、地区和细分市场进行预测，2024-2030 年

Cell-based Assays Market Size, Share & Trends Analysis Report By Products & Services (Reagents, Assay Kits), By Application (Basic Research, Drug Discovery), By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

细胞化验分析市场的成长和趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球细胞化验分析市场规模预计将达到338亿美元，2024年至2030年复合年增长率为8.8%。

对细胞化验分析的需求不断增长将推动市场的发展。基于细胞的检测可以有效帮助加速并从而增强药物开发。这将有助于确保治疗药物的稳定供应，以满足产业需求。例如，这些测定用于主要候选药物的选择，并提供有关治疗作用机制、药物功效、安全性和毒性测试的有价值的资讯。这些检测方法在药物开发过程中的广泛应用预计将推动需求。透过采用 CRISPR-Cas9 等多种技术，这些测定可以轻鬆解决基因组或细胞培养物中精确位置的特定标记的突变、敲入和敲除，从而已成为药物发现不可或缺的一部分。

例如，Celprogen的人类胰臟细胞株表征套件是一种基于细胞的ELISA试剂套件，用于测量细胞中的蛋白质浓度，以确定干细胞的分化状态，因而无需任何准备，可广泛应用于药物发现。同时，主要企业正在采取各种成长策略来扩大其管道、产品组合、产品线并渗透市场。例如，2022 年 7 月，Mission Bio, Inc. 透过其药物检测开发服务推出了一种检测固态肿瘤的检测方法，减少了表征固态肿瘤的时间和成本，并改善了癌症药物的开发过程。

此外，2022 年 4 月，Povile Sciences 将美国用于表观遗传学的 Chromatrap 晶片套件，以及我们在研究协会参展的用于高通量筛检过程、细胞增殖和细胞生长的新检测方法和新设计的细胞培养微孔盘。许多研究人员和临床医生正在寻找新的诊断效用的细胞基础和新的治疗方法，以有效对抗世界上日益增加的自体免疫、感染疾病和遗传性疾病的负担。的需求非常强烈。此外，COVID-19 大流行对研究活动的持续性和所进行的检测类型都造成了重大干扰。

在美国境内，正在努力确保恢復研究活动，包括所有类型的细胞检测。这些检测也用于检测 COVID-19 感染。例如，2020年5月，AcroBiosystem推出了流式细胞技术测定法来研究ACE2与S1蛋白/S1 RBD蛋白之间的结合。由于生物技术研究的增加、治疗药物研究的成长、主要参与者的存在以及癌症的高盛行率，北美在 2021 年将主导全球产业。由于生命科学研究需求不断增长以及对基因层面疾病的了解不断加深，亚太地区预计 2022 年至 2030 年复合年增长率最快。

细胞化验分析市场报告亮点

  • 由于检测套组可以为临床医生、研究人员和公众提供实际好处，检测套件产品领域在 2023 年占据了最大的收益占有率。
  • 现成的试剂套件和自我管理的诊断试剂套件如今越来越流行。
  • 预计药物发现应用领域在预测期内将以良好的复合年增长率成长。
  • 这是由于药物检索数量的增加、FDA核准的增加、对新疗法的需求增加以及遗传疾病、癌症和感染疾病病例的增加。
  • 学术和研究最终用途领域预计在预测期内复合年增长率最快。
  • 这种增长是由于细胞化验分析在诊断癌症、遗传性疾病和感染疾病的效用不断提高而推动的。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章细胞化验分析市场变数、趋势和范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 细胞化验分析市场分析工具
    • 波特的分析
    • PESTEL分析

第 4 章细胞化验分析市场：按产品/服务进行估算和趋势分析

  • 细分仪表板
  • 细胞化验分析市场：2023 年和 2030 年产品与服务变化分析
  • 试剂
  • 检测试剂套件
  • 微孔盘
  • 探针和标籤
  • 设备和软体
  • 细胞株

第五章细胞化验分析市场：依应用进行趋势分析

  • 细分仪表板
  • 细胞化验分析市场：应用变化分析，2023 年和 2030 年
  • 基础调查
  • 药物发现
  • 其他用途

第六章细胞化验分析市场：依最终用途估算与趋势分析

  • 细分仪表板
  • 细胞化验分析市场：最终用户变异分析，2023 年和 2030 年
  • 製药和生物技术公司
  • 学术研究所
  • 受託研究机构（CRO）

第七章细胞化验分析市场：区域估计和趋势分析

  • 2023 年和 2030 年按地区分類的细胞化验分析市场占有率
  • 美国
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Bio-Rad Laboratories, Inc.
    • Corning Incorporated
    • Merck KGaA
    • Lonza Group AG
    • Charles River Laboratories
    • Becton, Dickinson and Company（BD）
    • Danaher Corporation
    • Promega Corporation
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche Ltd.（Roche Holdings AG）
    • Perkin Elmer Inc.
简介目录
Product Code: GVR-4-68039-984-4

Cell-based Assays Market Growth & Trends:

The global cell-based assays market size is expected to reach USD 33.8 billion by 2030, registering a CAGR of 8.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. A rise in demand for cell-based assays will drive the market. Cell-based assays effectively aid in acceleration and thereby, enhancement of drug development. This helps therapeutic drugs to be supplied robustly to cater to the industry demand. For instance, these are used in lead candidate selection and provide invaluable information about therapeutic action mechanisms, drug efficacy, safety, and toxicity tests. Wide applications of these assays in drug development processes are expected to boost the demand. These assays are integral to the drug development process by adopting several technologies, such as CRISPR-Cas9, to allow easy resolution of mutations, knock-ins & knockouts of a specific marker at a precise location on the genome or a given culture of cells.

For instance, Celprogen's human pancreatic cancer cell line characterization kit is a cell-based ELISA kit that is used for the measurement of the concentration of a protein in cells for the determination of the differentiation status of stem cells, thereby eliminating the need to prepare cell lysates and is widely applicable for drug discovery. On the other hand, key players are undertaking various growth strategies to expand their pipelines, portfolios, and offerings to penetrate the market better. For instance, in July 2022, Mission Bio, Inc., launched assay for the detection of solid tumors through its pharma assay development services to aid the acceleration of the development process of cancer therapeutics by reducing the time & cost to characterize solid tumors.

Moreover, in April 2022, Porvair Sciences exhibited Chromatrap chip kits for epigenetics along with a new range of assay and newly designed cell culture microplates for high throughput screening process, cell growth, and proliferation at the American Association for Cancer Research. Many researchers and clinicians believe that there is a strong necessity for novel cell-based assays for their utility in diagnostics and to devise new therapeutic regimes to effectively combat the growing burden of autoimmune diseases, infectious diseases, and genetic disorders across the globe. Furthermore, the COVID?19 pandemic was substantially disruptive both to the continuance of research activities and the type of assays performed.

There are efforts across the U.S. to ensure re-igniting the research activities inclusive of all kinds of cell-based assays. These assays are used for the detection of COVID-19 infection as well. For instance, in May 2020, AcroBiosystem launched a flow cytometry assay to study the binding between ACE2 and S1 protein/S1 RBD protein, thus can be utilized for neutralizing antibody screening. North America dominated the global industry in 2021 owing to an increasing number of biotechnology research studies, growing research on therapeutic drugs, the presence of key players, and the high prevalence of cancer. Asia Pacific is expected to register the fastest CAGR from 2022 to 2030 due to the rising demand for research in life sciences and increased genetic level understanding of diseases.

Cell-based Assays Market Report Highlights:

  • The assay kits products segment accounted for the largest revenue share in 2023 due to the utilitarian benefits that a test kit could offer to clinicians, researchers, and the normal population.
  • Ready-to-use kits and self-administrable diagnostic kits are increasingly trending these days.
  • The drug discovery application segment is expected to grow at a lucrative CAGR over the forecast period.
  • This is due to a rise in the number of researches for therapeutic drug discovery, an increasing number of FDA approvals, and a rise in demand for novel therapeutic drugs coupled with increasing cases of genetic disorders, cancers, & infectious diseases.
  • The academic & research institutes end-use segment is expected to register the fastest CAGR over the forecast period.
  • The growth can be attributed to the greater utility of cell-based assays for the diagnosis of cancers, genetic disorders, and infectious diseases.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Cell-based Assays Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Cell-based Assays Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Cell-based Assays Market: Products & Services Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Cell-based Assays Market: Products & Services Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Reagents
    • 4.3.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Assay Kits
    • 4.4.1. Assay Kits Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. Cell Growth Assays
      • 4.4.2.1. Cell Growth Assays Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.3. Reporter Gene Assays
      • 4.4.3.1. Reporter Gene Assays Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.4. Cell Death Assays
      • 4.4.4.1. Cell Death Assays Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.5. Second Messenger Assays
      • 4.4.5.1. Second Messenger Assays Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Microplates
    • 4.5.1. Microplates Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Probes & Labels
    • 4.6.1. Probes & Labels Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Instruments & Software
    • 4.7.1. Instruments & Software Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Cell Lines
    • 4.8.1. Cell Lines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.8.2. Primary Cell Lines
      • 4.8.2.1. Primary Cell Lines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.8.3. Stem Cell Lines
      • 4.8.3.1. Stem Cell Lines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.8.4. Immortalized Cell Lines
      • 4.8.4.1. Immortalized Cell Lines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Cell-based Assays Market: Application & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Cell-based Assays Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Basic Research
    • 5.3.1. Basic Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Drug Discovery
    • 5.4.1. Drug Discovery Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Other Applications
    • 5.5.1. Other Applications Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Cell-based Assays Market: End use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Cell-based Assays Market: End-user Movement Analysis, 2023 & 2030 (USD Billion)
  • 6.3. Pharmaceutical & Biotechnology Companies
    • 6.3.1. Pharmaceutical & Biotechnology Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.4. Academic & Research Institutes
    • 6.4.1. Academic & Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.5. Contract Research Organizations (CROs)
    • 6.5.1. Contract Research Organizations (CROs)Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Cell-based Assays Market: Regional Estimates & Trend Analysis

  • 7.1. Cell-based Assays Market Share, By Region, 2023 & 2030 (USD Billion)
  • 7.2. U.S.
    • 7.2.1. U.S. Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3. Europe
    • 7.3.1. Europe Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.2. UK
      • 7.3.2.1. UK Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.4. France
      • 7.3.4.1. France Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.3. China
      • 7.4.3.1. China Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.4. India
      • 7.4.4.1. India Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Latin America
    • 7.5.1. Latin America Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Bio-Rad Laboratories, Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/Strategic Initiatives
    • 8.4.2. Corning Incorporated
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/Strategic Initiatives
    • 8.4.3. Merck KGaA
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/Strategic Initiatives
    • 8.4.4. Lonza Group AG
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/Strategic Initiatives
    • 8.4.5. Charles River Laboratories
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/Strategic Initiatives
    • 8.4.6. Becton, Dickinson and Company (BD)
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/Strategic Initiatives
    • 8.4.7. Danaher Corporation
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/Strategic Initiatives
    • 8.4.8. Promega Corporation
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/Strategic Initiatives
    • 8.4.9. Thermo Fisher Scientific Inc.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/Strategic Initiatives
    • 8.4.10. F. Hoffmann-La Roche Ltd. (Roche Holdings AG)
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/Strategic Initiatives
    • 8.4.11. Perkin Elmer Inc.
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Recent Developments/Strategic Initiatives